Citadel Advisors
GTBP icon

Citadel Advisors’s GT Biopharma GTBP Stock Holding History

Citadel Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed -$550 – 14690
2023
Q1 		$550 Buy
+1
New +$573 ﹤0.01% 14470
2022
Q2 		– Sell
-21
Closed -$45K – 13338
2022
Q1 		$45K Sell
21
-3
-13% -$6.62K ﹤0.01% 12862
2021
Q4 		$54K Sell
24
-6
-20% -$22.4K ﹤0.01% 13207
2021
Q3 		$153K Buy
+30
New +$226K ﹤0.01% 12357

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Citadel Advisors's GTBP Position: Q2 2026 in Review

Citadel Advisors sold out of GT Biopharma (GTBP) in Q2 2026, closing a stake of 2,647 shares — an estimated $27K sold.

Citadel Advisors first reported a position in GTBP in Q2 2021 and held it in 11 quarters. The position peaked at $7.91M in Q2 2021. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Citadel Advisors reported no remaining GT Biopharma position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 2,647 GT Biopharma shares in Q2 2026, an estimated $27K.
  • Citadel Advisors first reported a position in GT Biopharma in Q2 2021 and held it in 11 quarters.
  • Citadel Advisors's GT Biopharma position peaked at $7.91M in Q2 2021.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.